| Date | Title | Description |
| 18.03.2022 | Ampersand Health – NHSX today at #REWIRED22 announced the latest winners from the second cohort of the Digital Health Partnership Award. | Ampersand Health are excited to be working in partnership with St George’s University Hospitals NHS Foundation Trust, Thriva Health and Firefly Scientific Limited to collaboratively implement new patient pathways, underpinned by our integra... |
| 25.02.2022 | Centauri Therapeutics closes £24 million GBP Series A investment round | London, UK, 16 February 2022: Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, today announced the close of its £24 million GBP (c. 32 ... |
| 17.11.2021 | Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform | REẖOVOT, Israel, November 15, 2021 (Newswire.com) – Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform.
Curesponse is a cancer precision medicine company whose plat... |
| 12.05.2021 | Sana Health Receives FDA “Breakthrough Device Designation” for Sana Device as At-Home aid for Fibromyalgia | LAFAYETTE, CO
Sana Health ( http:///www.sana.io ) , a Colorado-based medical technology startup backed by global hard tech investor firm SOSV and Founders Fund, announces designation of its non-invasive at-home therapy as a “Breakthrough D... |
| 27.01.2021 | Ampersand Health launches a new digital therapeutic for people living with Inflammatory Arthritis | 19th January 2021, London: Ampersand Health, experts in digital therapeutics for long-term inflammatory conditions, announce the launch of My Arthritis DTx to support people living with Inflammatory Arthropathies, including Rheumatoid Arthr... |
| 21.10.2020 | Research by emteq labs reveals how emotion measurement could redefine treatment for anxiety, depression and PTSD | The AI Journal has covered the latest research by portfolio Emteq, acknowledging their current success milestones and the implications of their research for emotion measurement for the future.
“New research from the emotion-sensing wearabl... |
| 23.09.2020 | LifeArc and UK government’s Future Fund provide £3.0m in funding to Centauri Subsidiary Avvinity Therapeutics | LifeArc, an independent medical research charity,announces a £3.0m co-investment in British biotech Avvinity Therapeutics alongside the UK government’s Future Fund. Lead investor LifeArc leveraged £1.5m of seed funding provided to Avvinity ... |
| 22.09.2020 | Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing | Series B round led by Morningside Ventures provides foundation to accelerate the drug development of first-in-class immune-resetting therapies
(London UK and Boston USA, 21 September 2020) Immune Regulation Limited (“Immune Regulation”), a... |
| 17.09.2020 | Immune system ‘bully boys’ square up to coronavirus crisis | Scalable, affordable, effective. Read about TC Biopharm’s stunning progress in the Financial Times here.
“After winning approval from the UK’s Medicines and Healthcare Products Regulatory Agency to treat Covid-19 patients, the privately he... |
| 01.07.2020 | TC BioPharm C-19 Therapy Trials Approved | Porfolio company TC BioPharm has had their T-cell therapy approved for trials in Scotland for Covid-19 that would boost patients’ immune systems before their need for intensive care.
TC BioPharm has developed a method for cultivating lar... |
| 11.06.2020 | NCL is UK Lead of $6M Series A for Curesponse | NCL is delighted to welcome Curesponse to our portfolio, a breakthrough cancer precision medicine company. Their platform, cResponse, accurately and quickly predicts a patient’s response to cancer treatment.
The company’s platform, cRespon... |
| 06.04.2020 | TC BioPharm to begin trialling T-cell therapy against Covid-19 | Fantastic to see the Telegraph and the Daily Mail covering the work of TC BioPharm, one of our portfolio companies. Talks with government are taking place to begin trialing their T-cell cancer therapy against Covid-19. Happy our companies a... |
| 17.09.2019 | Award for ALERT at product launch! |
After an absolutely fantastic product launch last week, the team at Alert Technology are slowly coming back down to earth following this year’s Contamination Expo at the NEC, Birmingham.
We had an overwhelming response at the Expo from b... |
| 13.08.2019 | The child who inspired Andiamo – London’s most exciting tech firm | The agony suffered by tragic Diamo Parvez motivated parents Samiya and Naveed to alleviate the suffering of others through the use of an array of cutting-edge technology
Jonathan Symcox 9:00am 5th Aug 2019.
Andiamo is using Big Data, AI... |
| 09.05.2019 | These face-reading glasses track physical and mental health | Surgeon Charles Nduka has developed sensor tech to track facial expressions and is currently using it with patients with Parkinson’s. His next target: depression
Charles Nduka is a plastic surgeon who mends the bodies of his patients with ... |
| 02.04.2019 | New pharma Azadyne raises £1.5m for autoimmune disease treatment | Trinity College’s new spin-out organisation, Azadyne, has completed a £1.5million funding round for its new approach to the treatment of autoimmune diseases.
The Kent company focuses on an unexplored pathway in the body, with its novel app... |
| 04.03.2019 | Dolly the Sheep pioneer on brink of cancer treatment breakthrough | IT HAS been a professional crusade against deadly illness – and the scourge of cancer in particular – that has been marked at intervals by one amazing scientific breakthrough after another.
Among them, Angela Scott played a key role in the... |
| 14.02.2019 | TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products | – The first completed bio-banks will be used to develop more cost-effective, safe and efficacious cancer treatments
– Funding provided by European Horizon 2020 Research and Innovation program
Glasgow, UK, 22 January 2019: TC BioPharm (TCB... |
| 09.05.2018 | How bereaved parents became ‘accidental world leaders’ in 3D printing | Naveed and Samiya Parvez built a business so that other families wouldn’t have to suffer what they did.
The couple set up healthcare service Andiamo following the death of their nine-year-old son, Diamo. Diamo had cerebral palsy and relied... |
| 08.03.2018 | New £50m venture capital fund will give a shot in the arm to UK life sciences | A brand new £50m venture capital fund launches today with a plan to invest in the UK’s flourishing life sciences sector.
NCL Technology Ventures’ fund, which is backed by Kent County Council, will invest in high-growth small and medium-siz... |
| 08.03.2018 | New £50m venture capital fund will give a shot in the arm to UK life sciences | A brand new £50m venture capital fund launches today with a plan to invest in the UK’s flourishing life sciences sector.
NCL Investment Management’s fund, which is backed by Kent County Council, will invest in high-growth small and medium-... |
| 08.02.2018 | Scotland’s TCB inks CAR-T deal with Japan’s NIPRO | Scotland’s TC Biopharm (TCB) has secured a major investment from Japan with a deal centered on developing a novel gamma-delta CAR-T therapy to treat cancer, as well as a grant from Scottish Enterprise worth £2.7 million to fund preclinical ... |
| 21.12.2017 | Acerus Enters into a Licensing Agreement with Viramal to Commercialize the Elegant™ Franchise in Canada | Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has entered into a license, development and supply agreement with Viramal Limited (“Viramal”), a London-based specialty pharmaceutical company ... |
| 12.12.2017 | bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy | – Deal combines TC BioPharm’s leading gamma delta T Cell capabilities with bluebird’s proven expertise in all stages of CAR T and gene therapy product development to discover and develop next-generation liquid and solid tumor product candid... |
| 14.11.2017 | Age of Discovery (PharmaTimes, November 2017) |
Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future.
With around 150 companies working in 14 buildings over 440 acres, and several blockbuster ... |
| 21.03.2017 | NCL Innovation Leads Second Round of investment in Coomtech Ltd | Helping to secure market access for this energy company’s pioneering drying process.
NCL Innovation, the UK’s leading early stage technology investor, has joined a second financing round for Kent based start-up Coomtech Ltd. The investment... |
| 16.03.2017 | FutureNova FlipPad – Media Coverage in March 2017 | Following the news of the first US sales of FutureNova Ltd’s FlipPad® sterile iPad® case, the product has been receiving positive press coverage in a number of outlets:
|
| 08.03.2017 | NCL Innovation leads equity investment round into ‘game-changing’ technology destined to save thousands of lives through real time detection of airborne asbestos | NCL Innovation, the UK’s leading early stage technology investor, is leading a funding round for start-up Alert Technology, helping the innovative company to take its life saving technology from concept through to commercial success.
This ... |
| 15.02.2017 | Kent based sterile technology company FutureNova enjoys international success with first US sales with plans to scale up manufacturing to meet market demand from the health sector | FutureNova Ltd, backed by the Kent County Council run EXEK equity fund, has made its first successful sales in the United States with plans for a rapid scale up of its Kent based production process following a take-off in overseas demand fo... |
| 07.02.2017 | Discovery Park Technology Fund invests in pioneering clinical development company, TC BioPharm (TCB) providing a launchpad for clinical trials of new treatments for cancer and viral infections | In February 2016, the technology fund run by NCL Innovation, UK’s leading early stage technology investor, announced its support of TC BioPharm (TCB), directly investing seed-finance of £500k from a fund focused on cutting edge immunotherap... |
